Life Sciences Report (@SWLifeSciences) header
Life Sciences Report (@SWLifeSciences) profile picture

The Life Sciences Report, by Streetwise Reports, is the leading source of investment coverage of Biotech, Pharmaceuticals, Medical Devices, Tools & Diagnostics.

Joined December 2011
Photo by Life Sciences Report (@SWLifeSciences)Photo by Life Sciences Report (@SWLifeSciences)Photo by Life Sciences Report (@SWLifeSciences)Photo by Life Sciences Report (@SWLifeSciences)Photo by Life Sciences Report (@SWLifeSciences)Photo by Life Sciences Report (@SWLifeSciences)Photo by Life Sciences Report (@SWLifeSciences)Photo by Life Sciences Report (@SWLifeSciences)Photo by Life Sciences Report (@SWLifeSciences)Photo by Life Sciences Report (@SWLifeSciences)
Kyntra Bio Inc. (KYNB:NASDAQ) has reported its Q3 2026 results, showcasing a US$60 million reduction in royalty obligations. The company has strategically discontinued certain oncology programs and is now focusing on advancing its roxadustat Phase 3 trial for lower-risk MDS anemia. These decisions aim to streamline operations and better allocate resources, positioning Kyntra for future growth in the hematology sector. #KyntraBio #MDSAnemia #Pharmaceuticals #ClinicalTrials $KYNB streetwisereports.com/articl…
94
Cognition Therapeutics Inc. (CGTX:NASDAQ), in partnership with the Alzheimer's Clinical Trials Consortium, is presenting research at CTAD on plasma p-tau217 screening in its Phase 2 START Alzheimer's trial. This innovative approach aims to reduce participant and site burden as the company prepares for topline results expected in H2 2027. The findings could significantly impact the efficiency of Alzheimer's trials and patient recruitment. #CognitionTherapeutics #AlzheimersResearch #ClinicalTrials #HealthcareInnovation $CGTX streetwisereports.com/articl…
187
Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW2:XFRA) has successfully secured accreditation and completed Medicare and Medicaid enrollment for its flagship brain PET imaging clinic in Florida. This achievement marks a significant milestone in expanding access to advanced neuroimaging services, particularly for patients requiring brain scans for conditions like Alzheimer's disease. With the increasing reliance on confirmatory brain scans for new Alzheimer's treatments, Grey Matters is well-positioned to meet the growing demand for specialized neuroimaging. The recent policy changes that remove lifetime scan restrictions further enhance the clinic's potential to serve eligible patients effectively. As the company continues to innovate in brain health programs and testing initiatives, this development could attract interest from investors focused on healthcare advancements and neurodegenerative disease management. #GreyMattersHealth #Neuroimaging #Alzheimers #HealthcareInnovation #BrainHealth $GREY streetwisereports.com/articl…
127
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:FSE) has achieved 83% accuracy in its voice analytics for drug and alcohol detection, surpassing traditional methods. The company announced a CA$350,000 private placement to support commercialization efforts. Upcoming human testing will lead to a pilot product launch in Spanish, targeting industries like mining and aviation. streetwisereports.com/articl… #MindBio #VoiceAI #Biotech #TechInnovation #Safety $MBIO
127
Rezolute Inc. (RZLT:NASDAQ) shares are up ahead of the Phase 3 upLIFT topline results expected mid-December 2026! With a pre-BLA path for congenital hyperinsulinism and $90M in cash, the company is well-positioned for growth. They also highlighted a $5B market opportunity in their latest earnings. Read more: streetwisereports.com/articl… $RZLT #Pharma #Biotech
144
ProMIS Neurosciences Inc. (PMN:NASDAQ) is highlighting the antibody design and safety data for PMN310 following Acumen's Phase 2 setback. With a Q1 2027 Alzheimer's trial readout approaching, the company aims to differentiate itself in the competitive landscape. Read more: streetwisereports.com/articl… $PMN #Alzheimers #PharmaNews
188
BioLargo Inc. (BLGO:OTCQX) has launched barebird™, a new consumer odor-elimination brand built on its CupriDyne technology, backed by the marketing teams behind Pooph. This strategic move allows BioLargo to regain control over its brand and revenue, leveraging proven technology that previously generated over $125 million in sales. The initial product lineup includes fragrance-free pet and laundry odor eliminators, with plans for expansion into more household products. The brand aims to tap into the growing pet industry, projected to reach $165 billion in U.S. spending by 2026, and the global pet odor control market, expected to grow to $19.33 billion by 2034. Analysts highlight BioLargo's "hub and spoke" business model, which diversifies risk by commercializing technologies through subsidiaries. This approach positions BioLargo for significant growth in the consumer market. Read more: streetwisereports.com/articl… $BLGO #BioLargo #OdorElimination #ConsumerProducts
96
BioMarin Pharmaceutical Inc. (BMRN:NASDAQ) reported a 32% revenue growth to US$1.025 billion in Q3 2026, driven by its Amicus acquisition and expanding its Fabry disease pipeline. The company is also advancing regulatory applications for VOXZOGO, with a PDUFA date set for May 30, 2027, for hypochondroplasia. Despite the strong revenue, BioMarin has lowered its full-year guidance due to uncertainties around international orders and acquisition-related costs. The company expects total revenue between US$3.8 billion and US$3.9 billion for 2026. For more details, read the full article: streetwisereports.com/articl… $BMRN
1
186
Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW2:XFRA) is developing dedicated brain PET imaging clinics as new Alzheimer's treatments require follow-up scans. With Medicare lifting its once-per-lifetime restriction, demand for specialized imaging is set to rise. The company plans to open its first NovaScan clinic in Davie, Florida, and aims to establish a network of up to 200 clinics across the U.S., targeting a market projected to reach US$10.2 billion by 2026. For more details, read the full article: streetwisereports.com/articl… $GREY #Alzheimers #Healthcare #MedicalImaging
150
Novocure Ltd. (NVCR:NASDAQ) Q3 2026 Update Novocure Ltd. has reported record Q3 2026 net revenue of $193.4 million, marking a 16% increase year-over-year. The company has raised its full-year revenue guidance to between $736 million and $743 million, while also achieving its first positive adjusted EBITDA in over four years. This growth comes despite competitive pressures from KRAS inhibitors in the pancreatic cancer market. Key Highlights: - Record Revenue: Q3 revenue of $193.4 million reflects strong performance, driven by an increase in active patients and contributions from its Optune therapies. - Guidance Raised: The company has adjusted its full-year 2026 revenue guidance upward, indicating confidence in continued growth. - Regulatory Approval: Novocure secured approval for Optune Pax in Japan, expanding its market reach despite facing competition from KRAS inhibitors like daraxonrasib. - Positive EBITDA: The achievement of positive adjusted EBITDA signals a significant step towards profitability. Analysts remain cautiously optimistic, noting the potential for sustained growth as Novocure continues to navigate the competitive landscape. For more details, read the full article: streetwisereports.com/articl… #Novocure #Pharmaceuticals #PancreaticCancer #Optune #MarketUpdate
1
141
Rakovina Therapeutics Inc. (RKV:TSX.V; RKVTF:OTCPK; 7JO0:FSE) has expanded its AI-powered drug discovery agreement, securing exclusive rights to a defined ATR inhibitor profile and additional optimization work at no extra cost. This move enhances their efforts in developing brain-penetrant cancer therapies, particularly targeting tumors in the central nervous system. For more details, read the full article: streetwisereports.com/articl… #RakovinaTherapeutics #CancerResearch #AIDrugDiscovery
131
Virtual Care Platform Grows US Visits 56%, Eyes Record Quarter Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTCQB; 939:FSE) has reported a remarkable 56% increase in U.S. patient visits, totaling 53,348 in the third quarter. This surge positions the company for a record quarterly revenue, reflecting strong demand for its AI-driven telehealth services. Analysts highlight that Rocket Doctor AI is gaining meaningful traction in the U.S. market due to its innovative platform, which enhances healthcare access and efficiency. As the telehealth landscape evolves, Rocket Doctor AI is well-positioned to capitalize on the growing need for virtual care solutions. #RocketDoctorAI #Telehealth #AIHealthcare #PatientVisits streetwisereports.com/articl…
120
Diabetes Cell Therapy Merger Nears Close Ahead of Q1 2027 First Patient Dosing Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) is nearing the completion of its merger with Seraxis to form BetaNova, a company focused on type 1 diabetes cell therapy. This merger aims to leverage innovative technologies to provide a functional cure for diabetes. BetaNova plans to dose its first patient in Q1 2027, supported by over US$11.2 million in financing for a Phase 1/2 clinical trial. One analyst sees blockbuster potential in the combined pipeline, highlighting the synergy between Sernova's implantable Cell Pouch and Seraxis's stem cell-derived pancreatic islet cells. #Sernova #Seraxis #BetaNova #DiabetesTherapy #CellTherapy streetwisereports.com/articl…
1
200
MindBio Therapeutics Advances Voice AI Kiosk for Intoxication Detection MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:FSE) has completed the manufacturing of its next-generation Edge AI kiosk, which is designed for detecting intoxication through voice analysis. This advancement marks a significant step toward the first commercial pilot aimed at enhancing workplace safety screening. The kiosk utilizes proprietary Voice AI technology to provide rapid, non-invasive impairment detection, offering a more efficient alternative to traditional testing methods. The upcoming pilot will evaluate its effectiveness in real-world environments, with potential applications across various industries, including mining, aviation, and law enforcement. #MindBio #VoiceAI #WorkplaceSafety #IntoxicationDetection streetwisereports.com/articl…
1
147
NervGen Kicks Off Pivotal Phase 3 Test of NVG-291 in Chronic Spinal Cord Injury NervGen Pharma Corp. (NGEN:NASDAQ) has initiated its pivotal Phase 3 trial of NVG-291 for chronic spinal cord injury, dosing the first patient. Topline data is anticipated in the first half of 2028. However, one newsletter writer cautions that investors may face a lengthy wait for results, emphasizing the importance of patience in biotech investments. The outcome could significantly impact treatment options for spinal cord injuries. #NervGen #ChronicSpinalCordInjury #BiotechInvesting streetwisereports.com/articl…
1
2
362
Solving a 10,000-Pound Problem: This Company Aims to Reinvent the Brain Scan Grey Matters Health Inc. is on the verge of a breakthrough in medical imaging with the upcoming launch of its first dedicated brain PET imaging clinic. As new Alzheimer's treatments emerge, the demand for earlier and more specialized imaging has never been greater. This innovative approach aims to enhance diagnostic accuracy and improve patient outcomes by providing detailed insights into brain health. By focusing on advanced imaging techniques, Grey Matters Health is positioning itself at the forefront of a critical shift in how neurological conditions are diagnosed and treated. Could this be the key to revolutionizing brain health diagnostics? Stay tuned for updates on Grey Matters Health's journey and its impact on the future of Alzheimer's care! #GreyMattersHealth #BrainImaging #Alzheimers #MedicalInnovation #Healthcare streetwisereports.com/articl…
1
172
Sernova and Seraxis Bet on BetaNova to Take Diabetes Cell Therapy Into the Clinic. Sernova Biotherapeutics Inc. (SVA:TSX | SEOVF:OTCQB | PSH0:XETRA) and Seraxis Holdings Inc. are advancing toward a merger to create BetaNova Biotherapeutics, targeting a Type 1 diabetes cell therapy clinical trial in early 2027. #Biotech #PharmaNews #DiabetesResearch #CellTherapy #MarketUpdates streetwisereports.com/articl… Find out why one featured analyst believes Sernova has found the right strategic partner. Disclosure & Legal Disclaimer: Sponsored content. This post is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities. Early-stage biotechnology, clinical development, and stock investments carry high financial risk. Read our full disclosures and legal disclaimer via the link in our bio.
110
Nektar's Phase 2b Data Shows Durable Eczema, Alopecia Response. Nektar Therapeutics (NKTR:NASDAQ) reports durable Phase 2b responses for rezpegaldesleukin in eczema and alopecia areata, as the Treg-targeted drug advances toward Phase 3. streetwisereports.com/articl…
🤖 Made with AI
128